One of the advantages of the newer long-acting insulin analogs over current basal insulins is: Answer: C. Reduced risk for nocturnal hypoglycemia Explanation: The correct answer is reduced risk of nocturnal hyperglycemia. The newer fast-acting insulin analogs, U300 glargine or degludec, reach a more reliable and durable steady state, which results in a lower risk of nocturnal hyperglycemia. They are longer-acting, so they clear from the body less quickly. Unfortunately, they are still injections and are just as costly as the previous basal insulins. Lamos EM, et al. Ther Clin Risk Manag. 2016;12:389-400.
CorrectIncorrect